FAQ

ALO-02

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended-release… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe…
BACKGROUND The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
BACKGROUND ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to deter… (More)
Is this relevant?
Review
2016
Review
2016
Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
INTRODUCTION Chronic low back pain (CLBP) is a common and difficult illness to manage. Some individuals with CLBP have pain… (More)
Is this relevant?
2015
2015
Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
BACKGROUND AND OBJECTIVES ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride… (More)
Is this relevant?
2015
2015
Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
ALO-02 is an abuse-deterrent formulation consisting of capsules filled with pellets of extended-release oxycodone surrounding… (More)
Is this relevant?
2015
2015
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain…
The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the efficacy and… (More)
Is this relevant?
2015
2015
Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
WHAT IS KNOWN AND OBJECTIVE ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone… (More)
Is this relevant?
2014
2014
A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic…
OBJECTIVE To evaluate the long-term safety of oxycodone-hydrochloride and sequestered naltrexone-hydrochloride (ALO-02… (More)
Is this relevant?
2014
2014
Relative Bioavailability Study of an Abuse-Deterrent Formulation of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02) Versus Immediate-Release Oxycodone Tablets in Healthy Volunteers
Abbreviations: AE: Adverse Event; ALT: Alanine Aminotransferase; AUCinf: Area Under the Plasma Concentration-Time Profile from… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?